Platelet-rich Plasma vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology (PRP2009)

October 27, 2017 updated by: Istituto Ortopedico Rizzoli

Platelet-rich Plasma (PRP) vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology: a Randomized Double-blind Controlled Trial

The investigators hypothesized that intra-articular injections of Platelet-rich Plasma (PRP) to treat knee degenerative articular cartilage pathology could determine pain relief and recovery of knee function with overall clinical outcome comparable or even better than viscosupplementation, which is a common injective approach applied in this kind of pathology. To this purpose the investigators designed a double blind randomized controlled trial comparing PRP vs viscosupplementation.

A power analysis has been performed for the primary endpoint of IKDC (International Knee Documentation Committee) subjective score improvement at the 12-month follow-up for PRP. From a pilot study, a standard deviation of 15.2 points was found. With an alpha error of 0.05, a beta error of 0.2 and a minimal clinically significant difference of 6.7 points corresponding at 1/3 of the documented mean improvement, the minimum sample size was 83 for each group. Considering a possible drop out of 15%, 96 patients per group are required for total 192 patients, selected according to well-defined inclusion criteria (see 'Eligibility criteria' section). Patients are then assigned to two different treatment groups, according to a randomization list. The first group of treatment consists of three weekly intra-articular injections of autologous PRP obtained with the following procedure: a 150-ml autologous venous blood sample undergoes 2 centrifugations (the first at 1480 rpm for 6 minutes to separate erythrocytes, and a second at 3400 rpm for 15 minutes to concentrate platelets) to produced 20 ml of PRP. This unit of PRP is then divided into 4 small units of 5 ml each. One unit is sent to the laboratory for analysis of platelet concentration and for a quality test, 3 units are stored at -30° C.

The second treatment group consists of patients receiving three weekly injections of hyaluronic acid (Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy;Molecular Weight: 1500 kDa).

To guarantee the blinding of the patients, all of them undergo blood harvesting to obtain autologous PRP which will be used only in half of them, according to the aforementioned randomization list. One week after the PRP production, the injective treatment starts, with 3 weekly injections of PRP or HA. At the moment of the injection the syringe is properly covered to prevent the patient from discovering the substance he was receiving. After the injection, patients are sent home with instructions to limit the use of the leg for at least 24 h and to use cold therapy/ice on the affected area to relieve pain. During this period, the use of non-steroidal medication is forbidden.

Patients are prospectively evaluated basally and at 2, 6, and 12 months of follow-up using clinical subjective scores and objective parameters to determine clinical outcome (see 'Outcome measure' section). Patient satisfaction and adverse events will be also reported. All the clinical evaluations are performed by a medical staff not involved in the injective procedure, in order to keep the study double blinded. At the end of the study, the nature of the injected substance is revealed to the patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Current research is investigating new methods for stimulating repair or replacing damaged cartilage. In particular, the most recent knowledge regarding tissue biology highlights a complex regulation of growth factors (GFs) for the normal tissue structure and the reaction to tissue damage. The influence of GFs on cartilage repair is now widely investigated in vitro and in vivo. Platelet Rich Plasma (PRP) is a simple, low- cost and minimally- invasive method that allows one to obtain a natural concentrate of autologous GFs from the blood, and it is increasingly applied in the clinical practice to treat knee degenerative pathology, such as chondropathy and early osteoarthritis (OA). The biological rational of PRP is that platelets contain storage pools of GFs, cytokines, chemokines and many other mediators.Although its widespread application, there are no high level studies in the literature to demonstrate the real efficacy of PRP. In fact, at the present moment, to our knowledge there is no published randomized controlled trial comparing PRP with other conservative treatments commonly used for knee OA.

The investigators hypothesized that intra-articular injections of PRP to treat knee degenerative articular cartilage pathology could determine pain relief and recovery of knee function with overall clinical outcome comparable or even better than viscosupplementation, which is a common injective approach applied in this kind of pathology. To this purpose the investigators designed a double blind randomized controlled trial comparing PRP vs viscosupplementation.

A power analysis has been performed for the primary endpoint of IKDC subjective score improvement at the 12-month follow-up for PRP. From a pilot study, a standard deviation of 15.2 points was found. With an alpha error of 0.05, a beta error of 0.2 and a minimal clinically significant difference of 6.7 points corresponding at 1/3 of the documented mean improvement, the minimum sample size was 83 for each group. Considering a possible drop out of 15%, 96 patients per group are required for total 192 patients. Patients are then assigned to two different treatment groups, according to a randomization list. The first group of treatment consists of three weekly intra-articular injections of autologous PRP obtained with the following procedure: a 150-ml autologous venous blood sample undergoes 2 centrifugations (the first at 1480 rpm for 6 minutes to separate erythrocytes, and a second at 3400 rpm for 15 minutes to concentrate platelets) to produced 20 ml of PRP. This unit of PRP is then divided into 4 small units of 5 ml each. One unit is sent to the laboratory for analysis of platelet concentration and for a quality test, 3 units are stored at -30° C.

The second treatment group consists of patients receiving three weekly injections of hyaluronic acid (Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy;Molecular Weight: 1500 kDa).

To guarantee the blinding of the patients, all of them undergo blood harvesting to obtain autologous PRP which will be used only in half of them, according to the aforementioned randomization list. One week after the PRP production, the injective treatment starts, with 3 weekly injections of PRP or HA. At the moment of the injection the syringe is properly covered to prevent the patient from discovering the substance he was receiving. After the injection, patients are sent home with instructions to limit the use of the leg for at least 24 h and to use cold therapy/ice on the affected area to relieve pain. During this period, the use of non-steroidal medication is forbidden.

Furthermore, at the moment of each weekly injection, before injecting the substance, an attempt of harvesting synovial fluid is performed. During the same visit, also a peripheral blood sample (3 ml) is taken. These samples are then sent to a dedicated Laboratory in order to test the concentration of some GFs, pro and anti-inflammatory cytokines, both at local (synovial fluid) and systemic level (peripheral blood). The aim is to evaluate the trend in the concentration rate of these molecules over the period of the injective treatment.

Patients are prospectively evaluated basally and at 2, 6, and 12 months of follow-up using IKDC, KOOS (Knee Injury and Osteoarthritis Outcome Score), EQ-VAS (Visual Analogue Scale) for general health status, and Tegner scores. Furthermore at basal evaluation and at every follow-up the ROM (Range of Motion) and the transpatellar circumference of both the index knee and the contralateral one are measured to check if any changes occurred over time. Patient satisfaction and adverse events will be also reported.

During follow-up evaluations, also a peripheral blood sample is harvested (as described before) in order to assess any eventual variation in the concentration of same GFs, pro and anti-inflammatory cytokines previously evaluated. All the clinical evaluations are performed by a medical staff not involved in the injective procedure, in order to keep the study double blinded. At the end of the study, the nature of the injected substance is revealed to the patients.

Study Type

Interventional

Enrollment (Actual)

192

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
    • Emilia Romagna
      • Bologna, Emilia Romagna, Italy, 40136
        • III Orthopaedic Clinic and Nano-biotechnology Lab, Rizzoli Orthopaedic Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • patients affected by knee articular degenerative pathology with history of chronic (for at least 4 months) pain or swelling;
  • imaging findings of degenerative changes of the joint (Kellgren Lawrence 0 to III at X-ray evaluation).

Exclusion Criteria:

  • age > 80 years;
  • Kellgren-Lawrence score at X-ray evaluation > 3;
  • major axial deviation (varus >5° , valgus > 5°),
  • systemic disorders such as diabetes, rheumatoid arthritis, haematological diseases (coagulopathy), severe cardiovascular diseases, infections, immunodepression;
  • patients in therapy with anticoagulants or antiaggregants;
  • use of NSAIDs in the 5 days before blood donation;
  • patients with Hb values < 11 g/dl and platelet values < 150,000/mmc.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PRP Group
Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of autologous Platelet-Rich Plasma one week apart each other.
Biological: PRP
Active Comparator: Hyaluronan Group
Patients (n=96) randomized to this group of treatment will receive 3 blinded knee intra-articular injections of hyaluronic acid ( Hyalubrix 30 mg/2ml, Fidia Farmaceutici Spa, Italy) one week apart each other.
Device: Hyaluronic acid
Other Names:
  • Hyalubrix fl. 30 mg/2ml, Fidia farmaceutici Spa, Italy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
IKDC (International Knee Documentation Committee) subjective score variation for both groups of treatment at 12 months of follow-up (f-up)
Time Frame: baseline and 12 months of follow-up
baseline and 12 months of follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
IKDC (International Knee Documentation Committee) subjective score variation for both groups of treatment at 6 months of follow-up (f-up)
Time Frame: baseline and 6 months of follow-up
baseline and 6 months of follow-up
IKDC (International Knee Documentation Committee) subjective score variation for both groups of treatment at 2 months of follow-up (f-up)
Time Frame: baseline and 2 months of follow-up
baseline and 2 months of follow-up
IKDC (International Knee Documentation Committee) objective score variation for both groups of treatment at 12 months of follow-up (f-up)
Time Frame: baseline and 12 months of follow-up
baseline and 12 months of follow-up
IKDC (International Knee Documentation Committee) objective score variation for both groups of treatment at 6 months of follow-up (f-up)
Time Frame: baseline and 6 months of follow-up
baseline and 6 months of follow-up
IKDC (International Knee Documentation Committee) objective score variation for both groups of treatment at 2 months of follow-up (f-up)
Time Frame: baseline and 2 months of follow-up
baseline and 2 months of follow-up
VAS (Visual Analogue scale) for General Health Status variation for both groups of treatment at 12 months of follow-up (f-up)
Time Frame: baseline and 12 months of follow-up
baseline and 12 months of follow-up
VAS (Visual Analogue scale) for General Health Status variation for both groups of treatment at 6 months of follow-up (f-up)
Time Frame: baseline and 6 months of follow-up
baseline and 6 months of follow-up
VAS (Visual Analogue scale) for General Health Status variation for both groups of treatment at 2 months of follow-up (f-up)
Time Frame: baseline and 2 months of follow-up
baseline and 2 months of follow-up
Tegner score variation for both groups of treatment at 12 months of follow-up (f-up)
Time Frame: baseline and 12 months of follow-up
baseline and 12 months of follow-up
Tegner score variation for both groups of treatment at 6 months of follow-up (f-up)
Time Frame: baseline and 6 months of follow-up
baseline and 6 months of follow-up
Tegner score variation for both groups of treatment at 2 months of follow-up (f-up)
Time Frame: baseline and 2 months of follow-up
baseline and 2 months of follow-up
KOOS (Knee injury and Osteoarthritis Outcome Score) variation for both groups of treatment at 12 months of follow-up (f-up)
Time Frame: baseline and 12 months of follow-up
baseline and 12 months of follow-up
KOOS (Knee injury and Osteoarthritis Outcome Score) variation for both groups of treatment at 6 months of follow-up (f-up)
Time Frame: baseline and 6 months of follow-up
baseline and 6 months of follow-up
KOOS (Knee injury and Osteoarthritis Outcome Score) variation for both groups of treatment at 2 months of follow-up (f-up)
Time Frame: baseline and 2 months of follow-up
baseline and 2 months of follow-up
Knee Range of Motion (ROM) variation for both groups of treatment at 12 months of follow-up (f-up)
Time Frame: baseline and 12 months of follow-up
Every patient had both knees' ROM measured to eventually assess any variation between the treated and un-treated knee during the follow-up evaluation
baseline and 12 months of follow-up
Knee Range of Motion variation for both groups of treatment at 6 months of follow-up (f-up)
Time Frame: baseline and 6 months of follow-up
baseline and 6 months of follow-up
Knee Range of Motion variation for both groups of treatment at 2 months of follow-up (f-up)
Time Frame: baseline and 2 months of follow-up
baseline and 2 months of follow-up
Knee Trans patellar and distal quadriceps circumference variation for both groups of treatment at 12 months of follow-up (f-up)
Time Frame: baseline and 12 months of follow-up
baseline and 12 months of follow-up
Knee Trans patellar and distal quadriceps circumference variation for both groups of treatment at 6 months of follow-up (f-up)
Time Frame: baseline and 6 months of follow-up
baseline and 6 months of follow-up
Knee Trans patellar and distal quadriceps circumference variation for both groups of treatment at 2 months of follow-up (f-up)
Time Frame: baseline and 2 months of follow-up
baseline and 2 months of follow-up
Patient global satisfaction for the treatment
Time Frame: 12 months
12 months
Pain Level on a Visual Analogue Score after each intra-articular injection
Time Frame: 7 days after each injection
7 days after each injection
Swelling Level on a Visual Analogue Score after each injection
Time Frame: 7 days after each injection
7 days after each injection
Number of Participants with Adverse Events
Time Frame: 2, 6, 12 months of follow up
Type, duration and trend of every adverse event for each patient will be reported
2, 6, 12 months of follow up
Pain Duration after each intra-articular injection
Time Frame: 7 days after each injection
7 days after each injection
Swelling Duration after each injection
Time Frame: 7 days after each injection
7 days after each injection
Trend in the concentration of GFs and cytokines in synovial fluid
Time Frame: Baseline, day 7 (second injection), day 14 (third injection)
Baseline, day 7 (second injection), day 14 (third injection)
Trend in the concentration of GFs and cytokines in peripheral blood
Time Frame: Baseline, day 7 (second injection), day 14 (third injection), 2 months, 6 months, 12 months
Baseline, day 7 (second injection), day 14 (third injection), 2 months, 6 months, 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istituto Ortopedico Rizzoli

Investigators

  • Principal Investigator: Elizaveta Kon, MD, III Orthopaedic Clinic and Nano-biotechnology Lab, Rizzoli Orthopaedic Institute, Bologna, Italy

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2009

Primary Completion (Actual)

August 1, 2013

Study Completion (Actual)

May 1, 2014

Study Registration Dates

First Submitted

August 13, 2012

First Submitted That Met QC Criteria

August 20, 2012

First Posted (Estimate)

August 22, 2012

Study Record Updates

Last Update Posted (Actual)

October 30, 2017

Last Update Submitted That Met QC Criteria

October 27, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KNEEJECT

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis, Knee

Clinical Trials on PRP

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe